# Arcus Biosciences (RCUS) — Earnings

RCUS · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/rcus/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.72 |
| EPS estimate | −$0.89 |
| EPS surprise | +19.21% |
| Revenue surprise | +86.52% |
| Revenue | $41.0M |
| Revenue estimate | $22.0M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1724521/000172452126000044/rcus-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/3a004993-6b40-cccf-3116-4aeda1671113.html) |

Arcus Biosciences reported Q2 2026 results on August 5, 2026. It posted a loss of $0.72 per share, narrower than the $0.89 loss expected, a 19.21% beat. Revenue was $41.0 million, 86.52% above the $22.0 million consensus. Compared with Q2 2025, when EPS was $0.00 on revenue of $160.0 million, the result moved back to a loss and revenue fell about 74%.

Most quarters in the table are losses of roughly $0.90 to $1.14 per share on revenue of $17 million to $48 million. Three quarters stand out. Q4 2021 brought $354.5 million and a profit of $3.71 per share, Q1 2024 $145.0 million and a near break-even loss of $0.05, and Q2 2025 $160.0 million at break-even. Annual losses were $3.72 per share in 2022, $4.15 in 2023 and $3.10 in 2024. The table has no Q3 2025 row, so no 2025 total can be given. The first half of 2026 shows a combined loss of $1.74, against $1.14 a year earlier. Arcus beat the EPS estimate in 14 of the 20 quarters shown.

Q3 results came between November 2 and November 8 from 2021 to 2024. That points to early November 2026 for the next report.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | −$0.89 | −$0.72 | 19.21% | $22.0M | $41.0M |
| Q1 2026 | May 5, 2026 | −$0.88 | −$1.02 | -15.88% | $29.5M | $17.0M |
| Q4 2025 | Feb 25, 2026 | −$1.11 | −$0.89 | 19.55% | $35.7M | $33.0M |
| Q2 2025 | Aug 6, 2025 | −$1.13 | $0.00 | 100.00% | $33.2M | $160.0M |
| Q1 2025 | May 6, 2025 | −$1.03 | −$1.14 | -10.57% | $38.6M | $28.0M |
| Q4 2024 | Feb 25, 2025 | −$1.25 | −$1.03 | 17.51% | $29.3M | $36.0M |
| Q3 2024 | Nov 6, 2024 | −$1.06 | −$1.00 | 5.33% | $39.0M | $48.0M |
| Q2 2024 | Aug 8, 2024 | −$1.12 | −$1.02 | 8.52% | $26.2M | $39.0M |
| Q1 2024 | May 8, 2024 | −$1.01 | −$0.05 | 95.05% | $28.8M | $145.0M |
| Q4 2023 | Feb 21, 2024 | −$1.02 | −$1.08 | -5.41% | $28.3M | $31.0M |
| Q3 2023 | Nov 7, 2023 | −$1.13 | −$0.94 | 16.77% | $27.3M | $32.0M |
| Q2 2023 | Aug 7, 2023 | −$1.10 | −$1.04 | 5.31% | $31.8M | $29.0M |
| Q1 2023 | May 9, 2023 | −$1.16 | −$1.09 | 6.33% | $25.7M | $25.0M |
| Q4 2022 | Feb 28, 2023 | −$1.14 | −$0.93 | 18.38% | $23.7M | $34.0M |
| Q3 2022 | Nov 2, 2022 | −$1.04 | −$0.90 | 13.33% | $22.2M | $33.6M |
| Q2 2022 | Aug 3, 2022 | −$0.94 | −$0.93 | 1.19% | $21.6M | $26.8M |
| Q1 2022 | May 9, 2022 | −$0.85 | −$0.96 | -12.36% | $27.2M | $18.0M |
| Q4 2021 | Feb 23, 2022 | −$1.09 | $3.71 | 439.18% | $11.8M | $354.5M |
| Q3 2021 | Nov 8, 2021 | −$1.06 | −$1.11 | -5.00% | $9.4M | $9.5M |
| Q2 2021 | Aug 5, 2021 | −$0.87 | −$1.09 | -24.71% | $13.1M | $9.5M |

## Frequently Asked Questions

### When did Arcus Biosciences (RCUS) last report earnings?

Arcus Biosciences last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did RCUS beat earnings estimates?

Yes. Arcus Biosciences reported EPS of −$0.72 for Q2 2026 against a −$0.89 estimate — a 19.21% beat.

### How much revenue did RCUS report last quarter?

Arcus Biosciences reported $41.0M in revenue for Q2 2026, against a consensus estimate of $22.0M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).